This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2000;283:599-600.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

MMWR. 1999;48:1167-1171

2 tables omitted

Emerging mechanisms of antimicrobial resistance have clinical, microbiologic, and infection-control implications for health-care providers. Antimicrobial resistant organisms include Staphylococcus aureus with reduced susceptibility to vancomycin (minimum inhibitory concentration [MIC] 4 µg/mL), including vancomycin intermediate S. aureus (VISA; vancomycin MIC = 8-16 µg/mL)^1-4 and Enterobacteriaceae that produce extended spectrum -lactamases (ESBLS), which result in resistance to a broad range of -lactam antibiotics.⁵ Detecting VISA and ESBLs-producing gram-negative pathogens can be difficult for clinical microbiology laboratories. Although CDC^1-3,6 and the National Committee for Clinical Laboratory Standards (NCCLS)^7-9 have published screening and confirmatory methods for these pathogens, the extent of use of these methods is unknown. This report summarizes results from a survey of microbiology laboratories that participate in the Active Bacterial Core Surveillance (ABCs)/Emerging Infections Program (EIP) Network to assess the capacity of clinical microbiology laboratories to detect VISA and ESBL-producing pathogens; findings indicate that despite adequate . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?